Table 1 Protein kinases and their AD-relevant phosphosites.

From: Does modulation of tau hyperphosphorylation represent a reasonable therapeutic strategy for Alzheimer’s disease? From preclinical studies to the clinical trials

Kinases

AD-relevant phosphosites

GSK3

Ser46, Thr69, Thr149, Thr153, Thr175, Thr181, Ser184, Ser198, Ser199, Ser202, Thr205, Ser210, Thr212, Ser214, Thr217, Thr220, Thr231, Ser235, Ser237, Ser258, Ser262, Ser285, Ser289, Ser305, Ser324, Ser352, Ser356, Thr373, Ser396, Ser400, Ser404, Ser409, and Ser413

Cdk5

Thr153, Thr181, Ser195, Ser199, Ser202, Thr205, Thr212, Ser214,

Thr217, Thr231, Ser235, Ser396, and Ser404

p38 MAPK

Ser46, Thr69, Thr175, Thr181, Ser185, Ser202, Thr205, Thr212, Thr217, Thr231, Ser235, Thr245, Ser305, Ser320, Ser356, Ser396, Ser404, Ser409, and Ser422

DYRK1A

Ser202, Thr212, and Ser404

MARK4

Ser262 and Ser356

Src

Tyr18

Fyn

Tyr18

c-Abl

Tyr394

ROCK

Thr245, Thr377, Ser409